---
title: A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies
nct_id: NCT03421093
overall_status: COMPLETED
sponsor: West China Hospital
study_type: OBSERVATIONAL
primary_condition: Lung Cancer
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT03421093.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT03421093"
ct_last_update_post_date: 2018-05-21
last_seen_at: "2026-05-12T07:26:26.584Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# A Study to Evaluate Clinical Characteristics of Lung Cancer in Patients With Surgeries and Adjuvant Therapies

**Official Title:** A Multi-centre Real-world Non-interventional Observational Study to Evaluate Clinical Characteristics of the Chinese Patients With Lung Malignant Tumors Who Received Surgeries or Surgeries Plus Adjuvant Therapies

**NCT ID:** [NCT03421093](https://clinicaltrials.gov/study/NCT03421093)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 21777
- **Lead Sponsor:** West China Hospital
- **Collaborators:** LinkDoc Technology (Beijing) Co. Ltd.
- **Conditions:** Lung Cancer
- **Start Date:** 2017-12-01
- **Completion Date:** 2018-03-30
- **CT.gov Last Update:** 2018-05-21

## Brief Summary

The study was designed to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors

## Detailed Description

The trial is a multi-centre real-world non-interventional observational study to evaluate effectiveness of the surgeries and adjuvant therapies after surgeries in the patients with lung malignant tumors via a retrospectively review method on the study data on patient demographic/tumor biological characteristics and clinical treatments.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Age \>= 18 years old;
* Pathologically diagnosed lung malignant tumors after surgeries;
* Patients with lung surgeries;
* Patients with complete medical health records and follow-up visit information (at least one follow-up visit);

Exclusion Criteria:

* Patients who were not performed with surgeries;
* Pathologically diagnosed patients with benign diseases after surgeries;
```

## Arms

- **Surgeries and adjuvant therapies** — Surgeries or surgeries plus adjuvant therapies

## Interventions

- **Surgeries** (PROCEDURE) — Surgeries or surgeries plus adjuvant therapies

## Primary Outcomes

- **Demographic characteristics of the patients with lung malignant tumors who received surgeries** _(time frame: 2014 - 2017)_ — Demographic characteristics of the patients with lung malignant tumors who received surgeries of thoracotomy, video-assistant thoracic surgery or robotic thoracic surgery as measured by:

* Age
* Gender
* Payment types
* Insurance types
* Smoking history
* Complications and symptoms of complications
* Respiratory functions
* Type of diagnoses

## Secondary Outcomes

- **Location of tumors and tumor sizes** _(time frame: 2014 - 2017)_
- **Tumor clinical/pathological staging** _(time frame: 2014 - 2017)_
- **Type of biomarkers** _(time frame: 2014 - 2017)_

## Locations (10)

- China-Japan Friendship Hospital, Beijing, Beijing Municipality, China
- China PLA General Hospital, Beijing, Beijing Municipality, China
- Henan cancer hospital, Zhengzhou, Henan, China
- Tongji Hospital Affiliated to Huaxi Technology University, Wuhan, Hubei, China
- Jiangsu cancer hospital, Nanjing, Jiangsu, China
- Xi'an Tangdu Hospital, Xi'an, Shaanxi, China
- Shanghai Chest Hospital, Shanghai, Shanghai Municipality, China
- West China Hospital, Sichuan University, Chengdu, Sichuan, China
- Tianjin Chest Hospital, Tianjin, Tianjin Municipality, China
- First Hospital Affiliated to Zhejiang University, Hangzhou, Zhejiang, China

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `sponsor.collaborators` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.china-japan friendship hospital|beijing|beijing municipality|china` — added _(2026-05-12)_
- `locations.china pla general hospital|beijing|beijing municipality|china` — added _(2026-05-12)_
- `locations.henan cancer hospital|zhengzhou|henan|china` — added _(2026-05-12)_
- `locations.tongji hospital affiliated to huaxi technology university|wuhan|hubei|china` — added _(2026-05-12)_
- `locations.jiangsu cancer hospital|nanjing|jiangsu|china` — added _(2026-05-12)_
- `locations.xi'an tangdu hospital|xi'an|shaanxi|china` — added _(2026-05-12)_
- `locations.shanghai chest hospital|shanghai|shanghai municipality|china` — added _(2026-05-12)_
- `locations.west china hospital, sichuan university|chengdu|sichuan|china` — added _(2026-05-12)_
- `locations.tianjin chest hospital|tianjin|tianjin municipality|china` — added _(2026-05-12)_
- `locations.first hospital affiliated to zhejiang university|hangzhou|zhejiang|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT03421093.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT03421093*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*